(UroToday.com) It remains that African American (AA) men experience higher rates of incidence of prostate cancer and prostate cancer-specific mortality than do their non-AA counterparts. Multifaceted efforts are underway at several centers to isolate and address the biological and non-biological contributors to these fundamental health disparities. Among a gap between AA and non-AA prostate cancer patients is the rates of clinical trial enrollment.1 As advanced therapies have improved the outcomes for patients with metastatic castration-sensitive prostate cancer (mCSPC), the trials demonstrating these benefits have continued to underrepresent the AA community. In the absence of prospective data, Dr. Freeman and colleagues used retrospective data from six academic cancer centers to describe the clinical and genomic landscape of AA mCSPC.